Cingulate Inc. (CING) Operating Margin
- Operating margin · 12 months: Value (m); Formula and calculation Operating income / revenue. Period ending 2026-06-30..
Operating margin
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Operating margin · 12 months | (m) | Operating income / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Operating income | -24.92M USD | Operating Income (Loss) |
| Revenue | (m) | |
| Cost of products and services | (m) | |
| Research and development | 8.52M USD | Research and Development Expense |
| Selling, general and administration | (m) | Selling, General and Administrative Expense |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Operating income (USD) | Revenue (USD) | Cost of products and services (USD) | Research and development (USD) | Selling, general and administration (USD) | Operating margin |
|---|---|---|---|---|---|---|
| 2026-06-30 | $-24.92M | (m) | (m) | $8.52M | (m) | (m) |
| 2026-03-31 | $-24.16M | (m) | (m) | $9.74M | (m) | (m) |
| 2025-12-31 | $-19.94M | (m) | (m) | $9.77M | (m) | (m) |
| 2025-09-30 | $-20.56M | (m) | (m) | $12.10M | (m) | (m) |
| 2025-06-30 | $-17.85M | (m) | (m) | $10.68M | (m) | (m) |
| 2025-03-31 | $-16.40M | (m) | (m) | $9.86M | (m) | (m) |
| 2024-12-31 | $-15.64M | (m) | (m) | $9.45M | (m) | (m) |
| 2024-09-30 | $-16.23M | (m) | (m) | $10.10M | (m) | (m) |
| 2024-06-30 | $-18.70M | (m) | (m) | $12.60M | (m) | (m) |
| 2024-03-31 | $-21.86M | (m) | (m) | $15.17M | (m) | (m) |
| 2023-12-31 | $-22.76M | (m) | (m) | $15.49M | (m) | (m) |
| 2023-09-30 | $-20.44M | (m) | (m) | $12.44M | (m) | (m) |
| 2023-06-30 | $-18.66M | (m) | (m) | $10.64M | (m) | (m) |
| 2023-03-31 | $-16.34M | (m) | (m) | $8.36M | (m) | (m) |
| 2022-12-31 | $-17.50M | (m) | (m) | $9.00M | (m) | (m) |
| 2022-09-30 | $-15.67M | (m) | (m) | $8.33M | (m) | (m) |
| 2022-06-30 | $-26.98M | (m) | (m) | $11.99M | (m) | (m) |
| 2022-03-31 | $-24.36M | (m) | (m) | $10.61M | (m) | (m) |
| 2021-12-31 | $-20.68M | (m) | (m) | $8.41M | (m) | (m) |
| 2021-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-03-31 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-12-31 | $-7.08M | (m) | (m) | $5.09M | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| Lunai Bioworks Inc. (LNAI) | United States | $0.072B | -0.11 |
| PMV Pharmaceuticals, Inc. (PMVP) | United States | $0.071B | -0.95 |
| TENAX THERAPEUTICS, INC. (TENX) | United States | $0.071B | -7.17 |
| PLIANT THERAPEUTICS, INC. (PLRX) | United States | $0.071B | -0.76 |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| Yarrow Bioscience, Inc. (YARW) | United States | $0.070B | |
| Verrica Pharmaceuticals Inc. (VRCA) | United States | $0.076B | -3.39 |
| iBio, Inc. (IBIO) | United States | $0.077B | -2.94 |